SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis
USA - NASDAQ:SRPT - US8036071004 - Common Stock
18.81 USD
+0.99 (+5.56%)
18.76 USD
-0.05 (-0.27%)
Overall SRPT gets a fundamental rating of 3 out of 10. We evaluated SRPT against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of SRPT have multiple concerns. While showing a medium growth rate, SRPT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
SRPT had negative earnings in the past year.
In the past year SRPT has reported a negative cash flow from operations.
In the past 5 years SRPT reported 4 times negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
1.2 Ratios
SRPT has a Return On Assets of -7.77%. This is amongst the best in the industry. SRPT outperforms 86.06% of its industry peers.
SRPT has a Return On Equity of -20.57%. This is amongst the best in the industry. SRPT outperforms 83.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 76.25%, SRPT belongs to the best of the industry, outperforming 83.99% of the companies in the same industry.
SRPT's Gross Margin has been stable in the last couple of years.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRPT has more shares outstanding
The number of shares outstanding for SRPT has been increased compared to 5 years ago.
The debt/assets ratio for SRPT has been reduced compared to a year ago.
2.2 Solvency
SRPT has an Altman-Z score of -0.12. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.12, SRPT is in the better half of the industry, outperforming 60.64% of the companies in the same industry.
A Debt/Equity ratio of 0.78 indicates that SRPT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.78, SRPT is doing worse than 74.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.12 |
ROIC/WACCN/A
WACC7.27%
2.3 Liquidity
A Current Ratio of 2.95 indicates that SRPT has no problem at all paying its short term obligations.
SRPT has a Current ratio of 2.95. This is in the lower half of the industry: SRPT underperforms 64.03% of its industry peers.
A Quick Ratio of 1.79 indicates that SRPT should not have too much problems paying its short term obligations.
SRPT has a Quick ratio of 1.79. This is in the lower half of the industry: SRPT underperforms 77.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -197.60%.
Looking at the last year, SRPT shows a very strong growth in Revenue. The Revenue has grown by 47.15%.
The Revenue has been growing by 37.94% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
SRPT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.24% yearly.
SRPT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.07% yearly.
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y7.24%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.07%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 7.76, which indicates a rather cheap valuation of SRPT.
SRPT's Price/Forward Earnings ratio is rather cheap when compared to the industry. SRPT is cheaper than 98.49% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SRPT to the average of the S&P500 Index (34.59), we can say SRPT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.76 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.1%
EPS Next 3Y2.13%
5. Dividend
5.1 Amount
SRPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
18.81
+0.99 (+5.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners81.76%
Inst Owner Change-0.4%
Ins Owners4.63%
Ins Owner Change11.51%
Market Cap1.97B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts68
Price Target33.01 (75.49%)
Short Float %17.72%
Short Ratio2.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)0.25%
PT rev (3m)3.87%
EPS NQ rev (1m)-3.78%
EPS NQ rev (3m)-27.14%
EPS NY rev (1m)1.99%
EPS NY rev (3m)-5.44%
Revenue NQ rev (1m)2.72%
Revenue NQ rev (3m)-1.67%
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)6.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.76 | ||
| P/S | 0.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.49 | ||
| P/tB | 1.53 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.22
EYN/A
EPS(NY)2.42
Fwd EY12.88%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS23.06
BVpS12.61
TBVpS12.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% | ||
| FCFM | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 290.01% | ||
| Cap/Sales | 5.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | -0.12 |
F-Score3
WACC7.27%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y7.24%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.07%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.84%
EBIT Next 3Y13.2%
EBIT Next 5Y10.53%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRPT.
What is the valuation status of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.
How profitable is SAREPTA THERAPEUTICS INC (SRPT) stock?
SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.
What is the earnings growth outlook for SAREPTA THERAPEUTICS INC?
The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to decline by -292.84% in the next year.